US 12,221,422 B2
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
Nigel Ramsden, Babraham (GB); David John Fox, Coventry (GB); and James Andrew Huntington, Babraham (GB)
Assigned to CENTESSA PHARMACEUTICALS (UK) LIMITED, Altrincham (GB)
Filed by CENTESSA PHARMACEUTICALS (UK) LIMITED, Altrincham (GB)
Filed on Mar. 21, 2022, as Appl. No. 17/699,408.
Application 17/699,408 is a continuation of application No. 17/345,928, filed on Jun. 11, 2021, granted, now 11,312,689.
Application 17/345,928 is a continuation of application No. PCT/GB2019/053552, filed on Dec. 13, 2019.
Claims priority of application No. 1820450 (GB), filed on Dec. 14, 2018.
Prior Publication US 2022/0274932 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 239/36 (2006.01); A61K 9/00 (2006.01); A61P 1/16 (2006.01)
CPC C07D 239/36 (2013.01) [A61K 9/0053 (2013.01); A61P 1/16 (2018.01); C07B 2200/05 (2013.01)] 10 Claims
 
1. A method of inducing Z A1AT secretion comprising administering a compound represented by the structure of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt of any one thereof.